drugset

drugset / Trial / NCT06080854

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

NCT06080854 ↗

Phase 2 Unknown 108 enrolled The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Fudan University · collab Shanghai Changzheng Hospital · collab The First Affiliated Hospital of Soochow University · collab The First Affiliated Hospital with Nanjing Medical University · collab Xuzhou Central Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with potentially resectable pancreatic cancer.

Timeline

Start: 2023-11-10
Primary completion: 2025-06-06
Completion: 2026-06-06

Publications

Background Du J, Lu C, Mao L, Zhu Y, Kong W, Shen S, Tang M, Bao S, Cheng H, Li G, Chen J, Li Q, He J, Li A, Qiu X, Gu Q, Chen D, Qi C, Song Y, Qian X, Wang L, Qiu Y, Liu B. PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial. Cell Rep Med. 2023 Mar 21;4(3):100972. doi: 10.1016/j.xcrm.2023.100972. Epub 2023 Mar 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Nab-paclitaxel	Small molecule	125 mg/m2	Intravenous
Subject	Toripalimab	Monoclonal antibody	240 mg	Intravenous

Indications